Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Fold Holdings (NasdaqCM:FLD) with a Buy ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Alto Neuroscience (NYSE:ANRO) with a Buy ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

HC Wainwright lifted their Q1 2025 EPS estimates for Spectral AI in a note issued to investors on Wednesday, April 2nd. HC ...

H.C. Wainwright analyst Scott Buck lowered the firm’s price target on Knightscope (KSCP) to $12 from $16 and keeps a Buy rating on the shares.

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price target Alto is ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently ...

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently trading ...